Want to join the conversation?
In Jan. 2016, $ABBV announced the commencement of a Phase 3 clinical trial program to study the use of its once-daily formulation of ABT-494, its internally developed investigational selective Janus Kinase 1 inhibitor, for the treatment of rheumatoid arthritis. A Phase 2 trial of ABT-494 for the treatment of Crohn's disease is also ongoing.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.